USA Good Pharmacovigilance Practices 2026

USA Good Pharmacovigilance Practices 2026

November 12, 2026

Introduction

Good pharmacovigilance practice in the United States in 2026 means more than meeting reporting deadlines. It means running a safety system that is data-driven, inspection-ready and able to detect risks early.

Unlike the European Union, the US has no single document called “Good Pharmacovigilance Practices.” Instead, US expectations come from FDA regulations in the Code of Federal Regulations, a set of FDA guidance documents and internationally harmonised ICH guidelines. Together, they define how sponsors and application holders must collect, assess, report and act on safety information for drugs and biologics.

This article summarises the US framework, the core obligations, what is changing in 2026 and how organisations can build a pharmacovigilance system that stands up to FDA scrutiny.

The US regulatory framework

US pharmacovigilance rests on three layers: binding regulations and statute, FDA guidance, and harmonised ICH standards.

The US regulatory framework
Source What it covers
21 CFR 314.80 and 314.98 Postmarketing adverse drug experience reporting for NDA and ANDA holders
21 CFR 600.80 Postmarketing adverse experience reporting for licensed biologics
21 CFR 310.305 Reporting for marketed prescription drugs without an approved application
21 CFR 312.32 IND safety reporting during clinical development
21 CFR Part 4, Subpart B Postmarketing safety reporting for combination products
FD&C Act sections 505(o) and 505-1 Postmarketing requirements, safety labeling changes and REMS
FD&C Act section 760 Serious adverse event reporting for nonprescription drugs marketed without an approved application
FDA guidance: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment (2005) Signal identification, case series, pharmacovigilance plans and pharmacoepidemiologic studies
ICH E2B(R3), E2C(R2), E2D, E2E Electronic case reporting, periodic benefit-risk reports, postapproval safety data and pharmacovigilance planning

The 2005 FDA guidance is the closest US equivalent to the EU’s GVP modules. It remains the core reference for how FDA expects sponsors to identify and evaluate safety signals.

Core pharmacovigilance requirements

Every US application holder must run a documented system that captures, evaluates and reports safety information on time.

Written procedures

Applicants must have written procedures for the surveillance, receipt, evaluation and reporting of postmarketing adverse drug experiences. FDA inspectors review these procedures first, then test whether practice matches them.

Case processing

A valid case needs four minimum elements: an identifiable patient, an identifiable reporter, a suspect product and an adverse event. Cases come from spontaneous reports, literature, solicited programmes, studies, partners and social media monitored by the company.

Reporting timelines

Reporting timelines
Report type Timeline
Postmarketing 15-day Alert report (serious and unexpected) Within 15 calendar days of initial receipt
15-day Alert follow-up Within 15 calendar days of receiving new information
IND safety report (serious, unexpected suspected adverse reaction) Within 15 calendar days
IND safety report (fatal or life-threatening, unexpected) Within 7 calendar days
Periodic safety report (PADER, or PBRER where FDA has agreed) Quarterly for the first 3 years after approval, then annually

Signal management

Sponsors are expected to review safety data continuously, identify signals, evaluate them with appropriate methods and document decisions. Confirmed risks feed into labeling updates, communications and, where needed, risk management.

Risk management and REMS

Where labeling alone cannot manage a serious risk, FDA can require a Risk Evaluation and Mitigation Strategy. Sponsors must implement REMS elements and submit assessments on the agreed schedule.

Records and partners

Adverse drug experience records must be kept for 10 years (PolicyRisk). Safety data exchange agreements with licensing partners, distributors and vendors must make clear who receives, processes and reports each case.

What’s changing in 2026

The biggest US change in 2026 is mandatory E2B(R3) reporting from 1 October 2026. It sits alongside new FDA guidance on real-world evidence and pregnancy safety.

Mandatory E2B(R3) case reporting

From 1 October 2026, postmarketing ICSRs for human drugs, biologics and drug- or biologic-led combination products sent through the ESG NextGen gateway must use ICH E2B(R3) standards. FDA stopped accepting E2B(R2) ICSRs after 30 September 2026 (Federal Register, 6 April 2026). Reports now go to FDA’s Adverse Event Monitoring System (AEMS), formerly FAERS (RAPS).

Companies that are not yet E2B(R3)-capable can still use FDA’s Safety Reporting Portal. Once a submitter moves to E2B(R3), FDA expects every later ICSR to use it.

Real-world data for safety studies

On 4 March 2026, FDA issued final guidance on non-interventional studies that use real-world data, such as electronic health records and claims, to assess postmarketing safety. It stresses clear research questions, fit-for-purpose data sources and methods to handle bias and confounding. It also withdraws FDA’s 2013 guidance on safety studies using electronic healthcare data (RegASK).

Pregnancy safety studies

In May 2026, FDA finalised Postapproval Pregnancy Safety Studies: Guidance for Industry. It covers pharmacovigilance data, pregnancy registries and electronic data sources, and expects registry protocols to be submitted for FDA review before starting (RAPS).

AI in safety operations

AI is moving into case intake, coding, duplicate detection, literature screening and signal detection. FDA’s January 2025 draft guidance on AI to support regulatory decision-making sets a risk-based credibility framework. Sponsors using AI in pharmacovigilance should define each model’s context of use, validate it and keep humans accountable for medical judgement.

Active surveillance

FDA’s Sentinel System continues to expand its use of real-world data for active safety monitoring. This raises the bar for sponsors: FDA may detect a signal in its own data before the company does.

Common inspection findings and how to avoid them

FDA postmarketing adverse drug experience inspections tend to find the same recurring gaps. Most come from process and oversight weaknesses, not from a lack of technology.

Common inspection findings and how to avoid them
Common finding How to avoid it
Late 15-day Alert reports Track day-zero accurately across all intake channels, including partners and vendors
Incomplete or missing written procedures Keep SOPs current for every reporting obligation, and train staff against them
Cases not followed up Set follow-up rules for serious cases and document each attempt
Unreported adverse events from non-traditional sources Screen medical information, complaints, market research and patient programmes for safety data
Weak signal evaluation Document how signals are detected, assessed and closed, with clear decision rationale
Poor oversight of vendors and partners Maintain safety data exchange agreements, run reconciliations and audit service providers
Late or incomplete periodic reports Plan periodic reporting calendars and quality-check content before submission
REMS non-compliance Monitor REMS performance and submit assessments on schedule

Best-practice checklist for 2026

Use this checklist to test whether your US pharmacovigilance system is ready for 2026 and beyond.

  • All postmarketing ICSRs submitted in E2B(R3) format, or through the Safety Reporting Portal
  • Safety database validated for E2B(R3) and the FDA regional implementation guide
  • Written procedures cover every US reporting obligation and are reviewed at least annually
  • Day-zero tracking works across all intake channels, including partners and vendors
  • Safety data exchange agreements are current for every licensing partner and service provider
  • A documented signal management process with clear decision records
  • Periodic reporting calendar maintained, with PBRER waivers documented where used
  • REMS obligations monitored and assessments submitted on time
  • Real-world data studies designed in line with FDA’s 2026 final guidance
  • AI tools in pharmacovigilance validated, risk-assessed and overseen by qualified staff
  • Regular internal audits and mock FDA inspections
  • Training records complete for everyone who may receive safety information

Conclusion

Good pharmacovigilance practice in the US in 2026 is defined by speed, data quality and accountability. With E2B(R3) now mandatory, new FDA guidance on real-world evidence and pregnancy safety, and AI entering safety operations, the expectations on sponsors are rising.

The organisations that succeed will treat pharmacovigilance as a strategic capability, not a compliance cost. They will invest in validated systems, clear processes, strong partner oversight and skilled people who can turn safety data into timely decisions.

At Pharma Wizard Consultancy, we help life sciences companies build and run pharmacovigilance systems that meet FDA expectations and protect patients. From E2B(R3) readiness and case processing to signal management and inspection preparation, Pharma Wizard Consultancy can support your safety function at every stage. Contact us to discuss your pharmacovigilance needs.